ZUBOTAMIG
UNII 99MWR4VJT2
Substance Identification & Data
This profile provides standardized clinical and technical data for Zubotamig, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 99MWR4VJT2.
Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2640279-10-1 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.
99MWR4VJT2
2640279-10-1
N/A
Detailed Substance Profile
Preferred Name
ZUBOTAMIG
Official standardized name for this substance within the FDA UNII nomenclature system.
NCI Thesaurus
National Cancer Institute reference terminology for clinical and research data.
INN ID
13007
Sequential identifier assigned via the WHO International Nonproprietary Name program.
Substance Type
Zubotamig
ISO 11238 classification category (e.g., Chemical, Polymer, Protein).
Synonyms and Nomenclature
This section provides a complete list of nomenclature and identifier mappings for Zubotamig. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.
FDA Official Name
Zubotamig
Common Names & Synonyms
Immunoglobulin G1 [101-glycine,234-phenylalanine,235-glutamic acid,265-alanine,405-leucine,de-C-terminal-lysine], anti-(human CD3 antigen) (human-Mus musculus monoclonal IgG1-huCACAO-H101G-FEAL γ1-chain), disulfide with human-Mus musculus monoclonal IgG1-huCACAO-H101G-FEAL λ-chain, (234→226′),(237→229′)-bis(disulfide) with immunoglobulin G1 [234-phenylalanine,235-glutamic acid,265-alanine,409-arginine] anti-(human B7 homolog 4 protein) (human monoclonal IgG1-7724-084-N52S-FEAR γ1-chain) disulfide with human monoclonal IgG1-7724-084-N52S-FEAR κ-chain
RECOMBINANT BISPECIFIC HUMANISED IgG1 KAPPA ANTI-B7H4 MONOCLONAL ANTIBODY GEN1047 DS
immunoglobulin (H-gamma1_L-kappa)_(H-gamma1_L-lambda2), anti-[Homo sapiens VTCN1 (V-set domain containing T cell activation inhibitor 1, B7 family member H4, B7H4, B7-H4) and anti-[Homo sapiens CD3E (CD3 epsilon, Leu-4)], bispecific; H-gamma1 heavy chain anti-VTCN1 (1-446) [VH (Homo sapiens IGHV4-34*01 (95.9%) -(IGHD) -IGHJ5*01 (100%), CDR-IMGT [8.7.11] (26-33.51-57.96-106)) (1-117) -Homo sapiens IGHG1*03, G1m3, nG1m1 CH1 R120, CH3 E12, M14, G1v41 CH2 F1.3, E1.2, G1v66 CH2 A27, G1v82-2 CH3 R88 (CH1 R120 (214) (118-215), hinge 1-15 (216-230), CH2 L1.3>F (234), L1.2>E (235), D27>A (265) (231-340), CH3 E12 (356), M14 (358), K88>R (409) (341-445), CHS K2>del (446)) (118-446)], (220-214')-disulfide with L-kappa light chain (1'-214') [V-KAPPA (Homo sapiens IGKV1-17*01 (98.9%) -IGKJ1*01 (90.9%) K123>T (103'), CDR-IMGT [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153'), V101 (191') (108'-214')]; H-gamma1 heavy chain anti-CD3E (1''-454'') [VH Musmus/Homsap (Mus musculus IGHV10-1*02 (93.9%) -(IGHD) -IGHJ3*01 (93.3%) A128>S (125'')/Homo sapiens IGHV3-72*01 (81.0%) -(IGHD) -IGHJ6*01 (90.9%) T123>L (120''), CDR-IMGT [8.10.16] (26''-33''.51''-60''.99''-114'')) (1''-125'') -Homo sapiens IGHG1*03, G1m3, nG1m1 CH1 R120, CH3 E12, M14, G1v41 CH2 F1.3, E1.2, G1v66 CH2 A27, G1v82-1 CH3 L85.1 (CH1 R120 (222'') (126''-223''), hinge 1-15 (224''-238''), CH2 L1.3>F (242''), L1.2>E (243''), D27>A (273'') (239''-348''), CH3 E12 (364''), M14 (366''), F85.1>L (413'') (349''-453''), CHS K2>del (454'')) (126''-454'')], (228''-214''')-disulfide with L-lambda2 light chain (1'''-215''') [V-LAMBDA Musmus/Homsap (Mus musculus IGLV1*01 (83.3%) -IGLJ1*01 (100%)/Homo sapiens IGLV8-61*01 (70.8%) -IGLJ3*02 (100%), CDR-IMGT [9.3.9] (26'''-34'''.52'''-54'''.91''''-99'''') (1'''-109''') -Homo sapiens IGLC2*01 (100%) (110'''-215''')]; dimer (226-234'':229-237'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-K1SV, glycoform alfa
zubotamig [INN]
